Intraventricular tigecycline for the treatment of shunt infection: a case in pediatrics

Restricted access

Ventriculoperitoneal (VP) shunt infections are seen in 3%–17% of patients with VP shunts. These infections may cause severe morbidity and mortality. Staphylococci are the most common cause of CSF shunt-associated infections, although gram-negative bacteria (especially multidrug-resistant [MDR] and extensive drug–resistant [XDR] bacteria) also play an important role. Due to increased antibiotic resistance, sometimes off-label usage of antibiotics is considered. Tigecycline is one of these antibiotics. It should not be used unless there are no other antibiotic treatment options available, especially in children. It belongs to the glycylcycline class of antibiotic agents and inhibits protein translation in bacteria by binding to the 30S ribosomal subunit. The authors describe the case of a patient who had an XDR Klebsiella pneumoniae–positive VP shunt infection. After removal of his VP shunt, an external ventricular drain was inserted, and the patient was treated with a combination of intravenous (1.2 mg/kg/day) and intraventricular (4 mg/day) tigecycline in addition to his meropenem (120 mg/kg/day) treatment. On the 7th day of the combined therapy, his CSF culture was sterile. Because tigecycline distribution into the tissues is not sufficient with intravenous administration, combining it with intraventricular infusion can provide new treatment methods. However, further studies are needed for its use as a treatment method in children.

ABBREVIATIONS EVD = external ventricular drain; ICV = intra-cerebroventricular; IV = intravenous; IVT = intraventricular; MDR = multidrug resistant; MIC = mean inhibitory concentration; VP = ventriculoperitoneal; WBC = white blood cell; XDR = extensive drug resistant.

Article Information

Correspondence Berksu Curebal: Sisli Hamidiye Etfal Education and Research Hospital, Sisli, Istanbul, Turkey.

INCLUDE WHEN CITING Published online November 9, 2018; DOI: 10.3171/2018.9.PEDS18470.

Disclosures The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

© AANS, except where prohibited by US copyright law.




Cai YBai NLiu XLiang BWang JWang R: Tigecycline: Alone or in combination? Infect Dis (Lond) 48:4915022016


De Luca MAngelino GCalò Carducci FIMartino ABernardi SBernaschi P: Multidrug-resistant Acinetobacter baumannii infection in children. BMJ Case Rep 2011:bcr02201138072011


Emiroglu MAlkan GTurk Dagi H: Tigecycline therapy in an infant for ventriculoperitoneal shunt meningitis. Pediatrics 139:e201609632017


Fang YQZhan RCJia WZhang BQWang JJ: A case report of intraventricular tigecycline therapy for intracranial infection with extremely drug resistant Acinetobacter baumannii. Medicine (Baltimore) 96:e77032017


Iosifidis EViolaki AMichalopoulou EVolakli EDiamanti EKoliouskas D: Use of tigecycline in pediatric patients with infections predominantly due to extensively drug-resistant gram-negative bacteria. J Pediatric Infect Dis Soc 6:1231282017


Jaspan HBBrothers AWCampbell AJPMcGuire JKBrowd SRManley TJ: Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. Pediatr Infect Dis J 29:3793812010


Lauretti LD’Alessandris QGFantoni MD’Inzeo TFernandez EPallini R: First reported case of intraventricular tigecycline for meningitis from extremely drug-resistant Acinetobacter baumannii. J Neurosurg 127:3703732017


Magiorakos APSrinivasan ACarey RBCarmeli YFalagas MEGiske CG: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:2682812012


Pallotto CFiorio MD’Avolio ASgrelli ABaldelli FDi Perri G: Cerebrospinal fluid penetration of tigecycline. Scand J Infect Dis 46:69722014


Wang LZhang JYu XWang JCheng LHu S: Intrathecal injection of tigecycline in treatment of multidrug-resistant Acinetobacter baumannii meningitis: a case report. Eur J Hosp Pharm 24:1821842017


Woo PYMWong HTPu JKSWong WKWong LYLee MW: Primary ventriculoperitoneal shunting outcomes: a multicentre clinical audit for shunt infection and its risk factors. Hong Kong Med J 22:4104192016


Wu YChen KZhao JWang QZhou J: Intraventricular administration of tigecycline for the treatment of multidrug-resistant bacterial meningitis after craniotomy: a case report. J Chemother 30:49522018




All Time Past Year Past 30 Days
Abstract Views 53 53 53
Full Text Views 16 16 16
PDF Downloads 23 23 23
EPUB Downloads 0 0 0


Google Scholar